Kommentar zu: Primär biliäre Cholangitis: Elafibranor durchläuft erfolgreich Phase-III-Prüfung

• Literatur

• 1 Hirschfield GM, Bowlus CL, Mayo MJ. et al. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med 2024; 390: 783-794
• 2 Kowdley KV, Bowlus CL, Levy C. et al. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. N Engl J Med 2024; 390: 795-805
• 3 Nevens F, Andreone P, Mazzella G. et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 2016; 375: 631-643
• 4 Corpechot C, Chazouillères O, Rousseau A. et al. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018; 378: 2171-2181
• 5 Kowdley KV, Hirschfield GM, Coombs C. et al. COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls. Am J Gastroenterol 2024;